- Newsletter
- May 2024
Global
From €1010EUR$1,126USD£896GBP
- Report
- January 2022
- 419 Pages
Global
From €9131EUR$9,500USD£7,830GBP
- Report
- November 2021
- 101 Pages
Global
From €4325EUR$4,500USD£3,709GBP
- Drug Pipelines
- April 2021
- 64 Pages
Global
€21145EUR$22,000USD£18,133GBP
- Report
- July 2018
- 37 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Report
- April 2023
- 156 Pages
Global
€4806EUR$5,000USD£4,121GBP
- Report
- April 2023
- 114 Pages
Global
€3364EUR$3,500USD£2,885GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €481EUR$500USD£412GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£824GBP
Advair is a respiratory drug used to treat asthma and chronic obstructive pulmonary disease (COPD). It is a combination of two drugs, fluticasone and salmeterol, which work together to reduce inflammation and open up the airways. Advair is a long-acting bronchodilator, meaning it helps to keep the airways open for up to 12 hours. It is available in both inhaler and diskus form, and is typically prescribed for long-term maintenance of asthma and COPD.
Advair is one of the most widely prescribed respiratory drugs on the market, and is used by millions of people worldwide. It is a popular choice for those with asthma and COPD, as it is effective in controlling symptoms and reducing the risk of exacerbations.
Some of the companies in the Advair market include GlaxoSmithKline, Merck, AstraZeneca, and Boehringer Ingelheim. Show Less Read more
